STOCK TITAN

Regeneron Pharmaceuticals - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Overview

Regeneron Pharmaceuticals (NASDAQ: REGN) is a renowned American biotechnology company dedicated to inventing, developing, and commercializing transformative medicines for serious diseases. With its headquarters in Westchester County, New York, and a history dating back to 1988, Regeneron has established itself as a trusted innovator in the biopharmaceutical industry by consistently translating cutting‐edge science into life‐changing therapies.

Core Business and Technological Excellence

At the heart of Regeneron’s operations lies a deep commitment to scientific rigor and technological innovation. The company leverages proprietary VelociSuite® technologies, which include the groundbreaking VelocImmune® platform, to generate fully human antibodies and next-generation bispecific antibodies. These advanced techniques enable Regeneron to identify novel targets and rapidly develop therapies across a wide spectrum of indications such as eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic conditions, hematologic disorders, and rare diseases.

Research, Development and Collaborative Approach

Regeneron’s robust R&D engine is fueled by decades of biology expertise and an integrated approach to drug discovery. The company’s research framework harnesses data-powered insights and genetic medicine platforms to drive its clinical research programs. This commitment is reflected in its diverse pipeline of product candidates and regulatory pathways that emphasize both innovation and patient safety. Through strategic partnerships and collaborations with other key industry players, Regeneron further strengthens its technological capacity while expanding its reach in translational medicine.

Market Position and Significance in the Biotechnology Sector

In the competitive landscape of biotech and pharmaceuticals, Regeneron distinguishes itself through its consistent ability to translate scientific discoveries into marketed products. Its portfolio comprises therapies addressing complex diseases by utilizing targeted approaches involving monoclonal antibodies and complementary biologic modalities. The company’s methodical process—from early identification of druggable targets to rigorous clinical testing and eventual commercialization—underscores its expertise, high scientific standards, and commitment to improving patient outcomes.

Operational Strategy and Business Model

Regeneron generates revenue primarily through its commercialization of innovative therapies and strategic collaborations, which amplify its research capabilities. By focusing on conditions with significant unmet medical need, Regeneron positions itself as a dynamic entity capable of addressing diverse therapeutic challenges. Its strategies incorporate efficient drug development processes, collaborative research initiatives, and maintaining robust clinical trial portfolios—all without relying on time-sensitive information or financial forecasts.

E-E-A-T Focus and Investor Considerations

The company’s work is grounded in long-standing scientific expertise and a commitment to ongoing research. By adhering to stringent safety and efficacy protocols and maintaining transparent regulatory communications, Regeneron exemplifies the principles of Expertise, Experience, Authoritativeness, and Trustworthiness (E-E-A-T). For investors and analysts, Regeneron’s approach to innovation, its state-of-the-art proprietary technologies, and its history of successfully translating advanced science into viable therapies present a well-articulated model of modern biotechnology excellence.

Conclusion

Overall, Regeneron Pharmaceuticals represents a compelling example of how rigorous research, technological innovation, and strategic partnerships converge to create transformative medicines. Its consistent emphasis on high-quality science and unbiased, evidence-based development processes not only boosts its market presence but also reinforces its reputation as a trusted biopharmaceutical partner in the global healthcare arena.

  • Decades of scientific expertise
  • Innovative proprietary platforms
  • Diverse therapeutic pipeline
  • Robust R&D and clinical programs
  • Strategic collaborations and transparency
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies. The company will pay an upfront payment of $5 million and a single milestone payment from Regeneron to 2seventy bio for the first major market approval of the first approved product. Regeneron will also pay 2seventy bio a low single-digit percent royalty on revenues generated by the products. The transaction is expected to close in the first half of 2024 subject to certain closing conditions including SEC-filings required by 2seventy bio and landlord consent of the sublease agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. and Sanofi have announced the FDA approval of Dupixent for the treatment of pediatric patients aged 1 to 11 years with eosinophilic esophagitis (EoE). The approval expands the initial FDA approval for EoE in patients aged 12 years and older. The Phase 3 EoE KIDS trial showed that a greater proportion of children taking Dupixent achieved histological remission compared to placebo. The safety profile of Dupixent in children was generally similar to that observed in adult and pediatric patients aged 12 years and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. and Society for Science announce the top 40 finalists in the 2024 Regeneron Science Talent Search, showcasing exceptional young leaders in science and math. The finalists' research projects cover a wide range of topics, from brain disorders and suicide risk to local environment studies. The finalists will compete for more than $1.8 million in awards, with a top prize of $250,000. The competition received the largest pool of applicants since the 1960s, highlighting the increasing importance of scientific exploration and outreach programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi announced that the FDA has updated the label for Dupixent in atopic dermatitis, adding efficacy and safety data for patients aged 12 years and older with uncontrolled moderate-to-severe hand and/or foot involvement. The Phase 3 trial showed significant improvement in skin clarity and itch reduction for patients treated with Dupixent compared to placebo. The label update is based on data from the Phase 3 LIBERTY-AD-HAFT trial, with patients treated with Dupixent experiencing a 40% achievement of clear or almost clear skin on hands and feet compared to 17% with placebo, as well as a 52% reduction in itch compared to 14% with placebo. The safety profile of Dupixent remains consistent with known data, with common adverse events including injection site reactions, conjunctivitis, and others.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary
Medison Pharma (Medison) (NASDAQ: REGN) has announced an exclusive multi-national agreement with Regeneron Ireland DAC, a subsidiary of Regeneron Pharmaceuticals, to commercialize Libtayo (cemiplimab) in select European markets and additional markets worldwide. Libtayo is a leading PD-1 inhibitor approved for the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer, and advanced cervical cancer in more than two dozen countries. The agreement aims to continue patient access to this important therapy and facilitate a seamless transition of commercialization activities to Medison during the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will report its Q4 and full year 2023 financial and operating results on February 2, 2024. The conference call and webcast will be held at 8:30 AM Eastern Time on the same day. Participants can access the live webcast on the company's website or register in advance for the telephone conference call. A replay and transcript will be available on the website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences earnings
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the 'Investors & Media' page of Regeneron's website. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been included on the Dow Jones Sustainability World Index (DJSI World) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index (DJSI North America). Regeneron's dedication to sustainability is reflected in its consistent rankings, acknowledging the top 10 percent of the world's most sustainable companies in each industry. Regeneron stands proud as one of only five biotechnology firms globally to make the list, ranking among the top 2 percent. The company's improvement areas in this year’s assessment were climate strategy, labor practice indicators, and tax strategy. Regeneron's commitment to corporate responsibility is further highlighted by its impressive performance across various top ESG ratings and rankings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) presented positive data for odronextamab in patients with relapsed/refractory follicular lymphoma (FL) from a pivotal Phase 2 trial (ELM-2) at the 65th American Society of Hematology (ASH) Annual Meeting. The data demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced Phase 2 primary analysis results for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) at the 65th American Society of Hematology (ASH) Annual Meeting. The data showed a 52% objective response rate (ORR) and 31% complete response (CR) in the pivotal Phase 2 trial, with additional positive results from the Phase 1 trial. The primary analysis demonstrated impressive response rates, including in high-risk subgroups, and the potential treatment option for patients with this aggressive blood cancer. Odronextamab is currently under regulatory review for the treatment of R/R DLBCL and R/R FL by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $617 as of April 1, 2025.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 67.6B.

What is the core focus of Regeneron Pharmaceuticals?

Regeneron is a biotechnology company that specializes in discovering, developing, and commercializing innovative medicines for serious diseases using advanced scientific and technological approaches.

Which technologies underpin Regeneron’s research efforts?

The company utilizes its proprietary VelociSuite® and VelocImmune® platforms, which are central to its ability to generate fully human antibodies and next-generation bispecific antibodies.

In which therapeutic areas does Regeneron operate?

Regeneron develops therapies across several areas including eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic and hematologic conditions, as well as rare diseases.

How does Regeneron generate its revenue?

Revenue is primarily generated through the commercialization of approved therapies and strategic collaborations that enhance its research and development capabilities.

What differentiates Regeneron in the competitive biotech landscape?

Its commitment to cutting-edge technology, robust R&D pipeline, and a collaborative approach enable Regeneron to consistently transform scientific discoveries into marketable and efficacious treatments.

How long has Regeneron been active in the biotechnology field?

Regeneron was founded in 1988 and has since built a reputable track record for translating innovative science into transformative therapies.

What are the key elements of Regeneron’s business model?

The model emphasizes rigorous research and development, leveraging proprietary technologies, strategic partnerships, and a focus on addressing unmet medical needs while maintaining high standards of safety and efficacy.

How does Regeneron maintain its E-E-A-T (Expertise, Experience, Authoritativeness, Trustworthiness) standards?

By consistently investing in advanced research, adhering to strict clinical protocols, engaging transparently with regulatory authorities, and fostering innovations through collaborations, Regeneron demonstrates deep expertise and builds trust in the medical and investment communities.
Regeneron Pharmaceuticals

Nasdaq:REGN

REGN Rankings

REGN Stock Data

67.56B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
TARRYTOWN